For more than seventy years, the enzyme phosphofructokinase was understood as a faithful servant of cellular energy metabolism — a fixed landmark in the biochemistry of life. Researchers at the University of Surrey have now discovered that one of its subunits, Pfk2, quietly performs a second role: binding and unwinding RNA to govern when cells divide. The finding reframes a familiar molecule as a molecular diplomat between energy and growth, and invites the humbling question of how many other long-studied proteins carry secrets we have not yet thought to ask about.
Enzyme long studied for energy production has hidden role in cell division
Related Coverage
Academics propose a 2% wealth tax on UK households exceeding £100m, potentially raising £10bn yearly while affecting few…
Inquirer.net · Jul 21 Cotabato girl dies from rabies; health workers trace funeral attendees for vaccinationA Grade One student in Cotabato died from rabies after possible exposure through animal contact. Health authorities are …
The Energy Mix · Jul 21 Flow Batteries Scale Up: China's Breakthrough Sparks European CompetitionChina deployed the world's first large-scale flow battery project in January, with European developers building larger s…
CBS News · Jul 21 U.S. gas prices surge back to $4 a gallon amid Iran tensionsU.S. average gas prices have climbed back to $4 per gallon, rising 13 cents weekly as geopolitical tensions with Iran es…
Bias & Framing
No detailed analysis data available for this lens. Try re-running lenses from the admin panel.
Geopolitical Impact
This is a basic science discovery about enzyme function with no direct geopolitical implications; it has no bearing on international relations, power dynamics, or regional conflicts.
Economic Lens
Discovery of dual function in 70-year-old metabolic enzyme (PFK) with potential applications in cancer treatment and cell cycle regulation could drive biotech innovation and pharmaceutical development.
Long-term potential for improved cancer treatments and cell-cycle-related disease therapies; near-term impact minimal as research is in early stages; could reduce healthcare costs if therapies prove effective.
Potential acceleration of FDA approval pathways for novel cancer therapeutics; increased R&D tax incentives for biotech firms; possible patent framework discussions around enzyme-based therapies; regulatory guidance needed for RNA-targeting drug development.